Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria
Jayesh Sagar, Kevin Sales, Jan-Willem Taanman, Sas Dijk, Marc Winslet, Jayesh Sagar, Kevin Sales, Jan-Willem Taanman, Sas Dijk, Marc Winslet
Abstract
Background: Colorectal cancer is the third most-common cancer and the second most-common cause of cancer related death in UK. Although chemotherapy plays significant role in the treatment of colorectal cancer, morbidity and mortality due to drug resistance and cancer metastasis are yet to be eliminated. Recently, doxycycline has been reported to have cytotoxic and anti-proliferating properties in various cancer cells. In this study, whether doxycycline was apoptosis threshold lowering agent in colorectal cancer cells by targeting mitochondria was answered.
Results: This study showed dose-dependent cytotoxic effects of cisplatin, oxaliplatin and doxycycline in HT29 colorectal cancer cells. Doxycycline showed inhibition of cytochrome-c-oxidase activity in these cells over a time-period. The pre-treatment of doxycycline reported statistically significant increased cytotoxicity of cisplatin and oxaliplatin compared to cisplatin and oxaliplatin alone. The caspase studies revealed significantly less expression and activity of caspase 3 in HT29 cells pre-treated with doxycycline compared to the cells treated with cisplatin and oxaliplatin alone.
Conclusions: It was concluded that doxycycline lowered the apoptotic threshold in HT 29 cells by targeting mitochondria. This also raised possible caspase-independent mechanisms of apoptosis in HT29 cells when pre-treated with doxycycline however this needs further research work.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-4.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-5.jpg)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-6.jpg)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-7.jpg)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2940783/bin/1475-2867-10-31-8.jpg)
References
- Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs. 2003;14:773–778. doi: 10.1097/00001813-200311000-00001.
- Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 2002;98:297–309. doi: 10.1002/ijc.10168.
- Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG. et al.Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis. 1998;16:217–225. doi: 10.1023/A:1006588708131.
- Cakir Y, Hahn KA. Direct action by doxycycline against canine osteosarcoma cell proliferation and collagenase (MMP-1) activity in vitro. In Vivo. 1999;13:327–331.
- Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG. et al.Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 2002;62:1588–1591.
- Iwasaki H, Inoue H, Mitsuke Y, Badran A, Ikegaya S, Ueda T. Doxycycline induces apoptosis by way of caspase-3 activation with inhibition of matrix metalloproteinase in human T-lymphoblastic leukemia CCRF-CEM cells. J Lab Clin Med. 2002;140:382–386. doi: 10.1067/mlc.2002.129308.
- Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem. 2001;8:261–270.
- D'Agostino P, Ferlazzo V, Milano S, La RM, Di BG, Caruso R. et al.Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway. Int Immunopharmacol. 2003;3:63–73. doi: 10.1016/S1567-5769(02)00213-8.
- Schwartz LM, Smith SW, Jones ME, Osborne BA. Do all programmed cell deaths occur via apoptosis? Proc Natl Acad Sci USA. 1993;90:980–984. doi: 10.1073/pnas.90.3.980.
- Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312–1316. doi: 10.1126/science.281.5381.1312.
- Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol. 2002;50:343–352. doi: 10.1007/s00280-002-0522-7.
- Makin G, Dive C. Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol Med. 2003;9:251–255. doi: 10.1016/S1471-4914(03)00084-4.
- Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33–64. doi: 10.3322/canjclin.49.1.33. 1.
- Onoda T, Ono T, Dhar DK, Yamanoi A, Fujii T, Nagasue N. Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. J Lab Clin Med. 2004;143:207–216. doi: 10.1016/j.lab.2003.12.012.
- Onoda T, Ono T, Dhar DK, Yamanoi A, Nagasue N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 2006;118:1309–1315. doi: 10.1002/ijc.21447.
- Fife RS, Sledge GW, Roth BJ, Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett. 1998;127:37–41. doi: 10.1016/S0304-3835(98)00003-2.
- Fife RS, Rougraff BT, Proctor C, Sledge GW Jr. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med. 1997;130:530–534. doi: 10.1016/S0022-2143(97)90130-X.
- Mouratidis PX, Colston KW, Dalgleish AG. Doxycycline induces caspase-dependent apoptosis in human pancreatic cancer cells. Int J Cancer. 2007;120:743–752. doi: 10.1002/ijc.22303.
Source: PubMed